Alnylam post-earnings selloff overdone, says Citi

Citi analyst David Lebowitz lowered the firm’s price target on Alnylam Pharmaceuticals to $227 from $237 and keeps a Buy rating on the shares post the Q4 report. Despite continued strength in the ATTR franchise, Alnylam shares came under heavy pressure following the company’s update on primary endpoint shifts and a delayed HELIOS-B timeline, the analyst tells investors in a research note. The firm believes the recent weakness is overdone, saying these modifications likely improve the odds of capturing Amvuttra benefit, especially as monotherapy, maximizing frontline potential. It reiterates that HELIOS-B is likely to succeed and is are buyers on the recent weakness.